Your session is about to expire
← Back to Search
Vibroacoustic Stimulation for PTSD
Study Summary
This trial will test whether the Apollo wearable, which emits gentle vibrations, can help improve symptoms of PTSD following MDMA-assisted psychotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am unable to understand and give consent for treatment.I cannot complete questionnaires in English.You have already participated in the placebo group of the MAPS MDMA-Assisted Psychotherapy for PTSD clinical trial.You are enrolled in the MAPS MDMA-Assisted Psychotherapy for PTSD clinical trial, but dropped out.I am 18 years old or older.
- Group 1: MDMA-Assisted Psychotherapy Participants
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies available for this clinical trial's participants?
"Affirmative. According to clinicaltrials.gov, this research initiative is recruiting individuals and first appeared on December 8th 2021 with the most recent update occurring on July 19th 2022. 200 study participants are being sought out at a single medical centre."
What aims are investigators attempting to accomplish with this research?
"Apollo Neuroscience, Inc., the sponsor of this trial, seeks to evaluate Beck Depression Inventory II (BDI-II) scores over an average two year period as their primary outcome. Moreover, Drug Use Disorders Identification Test (DUDIT), Alcohol Use Disorders Identification Test (AUDIT), and Chronic pain Grade Scale (CPGS) will be used to assess secondary outcomes such as drug use frequency, alcohol consumption levels, and chronic pain severity respectively. CPGS is composed of three subscale measurements that assign subjects into one of five grades ranging from no pain to severely limiting pain intensity and disability."
How many participants will this research project admit?
"Affirmative. According to the information present on clinicaltrials.gov, this research endeavor is recruiting participants with vigor; it was first announced on December 8th 2021 and was most recently updated July 19th 2022. 200 individuals need to be recruited from 1 site."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger